Drug Trial Radar · NCT07000357
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15,100
Planned (sponsor's estimate)
Start
Jun 4, 2025
Primary completion
Oct 26, 2029
Study completion Oct 26, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 3, randomized, placebo controlled, event-driven study is to assess the effect of AZD0780, an oral PCSK9 inhibitor, compared with placebo in reducing the risk of MACE-PLUS in patients with established ASCVD or at high risk for a first ASCVD event. The effect of AZD0780 vs placebo on the risk of MACE-PLUS will be evaluated from randomisation until the primary analysis censoring date (PACD). The Study Closure Visit will be scheduled to occur after the PACD and will be the final visit for each participant in the study.
Conditions
- Cardiovascular Disease
Interventions
AZD0780Drug
Participants will receive oral AZD0780 once daily
PlaceboDrug
Participants will receive oral placebo once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first event of any component of MACE-PLUSTime frame: Up to approximately 54 months
Locations
1,452 sites in 36 countries. Site status is shown where the registry gives one.
Research Site
Athens, Alabama · Recruiting
Research Site
Birmingham, Alabama · Recruiting
Research Site
Birmingham, Alabama · Not yet recruiting
Research Site
Fairhope, Alabama · Recruiting
Research Site
Foley, Alabama · Recruiting
Research Site
Huntsville, Alabama · Withdrawn
Research Site
Huntsville, Alabama · Not yet recruiting
Research Site
Irondale, Alabama · Not yet recruiting
Research Site
Mobile, Alabama · Recruiting
Research Site
Northport, Alabama · Not yet recruiting
Research Site
Saraland, Alabama · Recruiting
Research Site
Vestavia Hills, Alabama · Recruiting
Research Site
Gilbert, Arizona · Not yet recruiting
Research Site
Gilbert, Arizona · Recruiting
Research Site
Glendale, Arizona · Terminated
Research Site
Mesa, Arizona · Withdrawn
Research Site
Peoria, Arizona · Recruiting
Research Site
Phoenix, Arizona · Not yet recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Phoenix, Arizona · Recruiting
Research Site
Scottsdale, Arizona · Recruiting
Research Site
Tempe, Arizona · Recruiting
Research Site
Tucson, Arizona · Recruiting
Research Site
Tucson, Arizona · Withdrawn
Research Site
Tucson, Arizona · Recruiting
Research Site
Little Rock, Arkansas · Recruiting
Research Site
Beverly Hills, California · Recruiting
Research Site
Canoga Park, California · Recruiting
Research Site
Castroville, California · Recruiting
Research Site
Chula Vista, California · Recruiting
Research Site
Fountain Valley, California · Recruiting
Research Site
Garden Grove, California · Recruiting
Research Site
La Jolla, California · Not yet recruiting
Research Site
Lake Forest, California · Withdrawn
Research Site
Lancaster, California · Recruiting
Research Site
Loma Linda, California · Recruiting
Research Site
Loma Linda, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Research Site
Los Angeles, California · Recruiting
Showing 40 of 1,452 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.